Financials data is unavailable for this security.
View more
Year on year Jazz Pharmaceuticals PLC grew revenues 4.78% from 3.66bn to 3.83bn. In addition the company has reduced the cost of goods sold, selling, general and administrative expenses and debt expenses (all as a percent of sales). The company reported positive net income, improving from a loss of 224.06m to a profit of 414.83m.
| Gross margin | 89.37% |
|---|---|
| Net profit margin | 11.65% |
| Operating margin | 16.24% |
| Return on assets | 3.97% |
|---|---|
| Return on equity | 12.09% |
| Return on investment | 4.46% |
More ▼
Cash flow in USDView more
In 2023, Jazz Pharmaceuticals PLC increased its cash reserves by 70.88%, or 624.83m. The company earned 1.09bn from its operations for a Cash Flow Margin of 28.48%. In addition the company used 163.06m on investing activities and also paid 305.25m in financing cash flows.
| Cash flow per share | 16.85 |
|---|---|
| Price/Cash flow per share | 6.78 |
| Book value per share | 69.01 |
|---|---|
| Tangible book value per share | -45.96 |
More ▼
Balance sheet in USDView more
| Current ratio | 4.26 |
|---|---|
| Quick ratio | 3.74 |
| Total debt/total equity | 1.47 |
|---|---|
| Total debt/total capital | 0.5944 |
More ▼
Growth rates in USD
Year on year, growth in earnings per share excluding extraordinary items increased 270.30%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
| EPS growth(5 years) | -3.53 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 709.80 |
